MarketLens

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Roche's Divarasib: A New Standard of Care Emerges to Challenge Amgen's KRAS Dominance

2 months ago

Has Accel Entertainment's Recent Performance Set a New Standard

6 months ago

A New Media Titan Emerges: What Does the Paramount-WBD Merger Mean

6 months ago

Why Did Gilead Pay $7.8 Billion for Arcellx

6 months ago

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Assembly Biosciences exercised its U.S. profit-share option with Gilead, agreeing to fund 40% of U.S. development costs and share 40% of profits for the HSV helicase-primase inhibitor program targetin...

ASMB

Stock News•1 months ago

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Gilead and Merck's once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for the first weekly regimen.

GILD

Stock News•2 months ago

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead Sciences is launching four new drugs this year in oncology and inflammation, following a spring acquisition spree. The launches could shift investor perception beyond its legacy HIV business.

GILD

Breaking News

Clinical Trials (Phase I, II, III)

Creator Economy

Crude Oil (WTI/Brent)

Top Headlines

View More →

Stock News•2 hours ago

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Stock News•2 hours ago

Viral AI Dommer Tweet: Engineered Panic?

Stock News•3 hours ago

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Stock News•4 hours ago

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Stock News•6 hours ago

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

Exclusive Content for Pro Members

Related Articles

Roche's Divarasib: A New Standard of Care Emerges to Challenge Amgen's KRAS Dominance

Has Accel Entertainment's Recent Performance Set a New Standard

A New Media Titan Emerges: What Does the Paramount-WBD Merger Mean

Why Did Gilead Pay $7.8 Billion for Arcellx

Category

You may also like

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Viral AI Dommer Tweet: Engineered Panic?

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Warren Buffett Made Apple Berkshire Hathaway's Single Largest Stock Position: $10,000 Invested 10 Years Ago Would Be Worth Roughly $122,400 Today